This study examines two treatments for metastatic castrate resistant prostate cancer (mCRPC), which is a type of prostate cancer that spreads and no longer responds to hormone therapy. Participants will receive either carboplatin, a chemotherapy drug given through an IV, or olaparib, a pill taken by mouth. Both treatments aim to damage cancer cell DNA. If the first treatment stops working, participants can switch to the other treatment. The study targets patients with specific gene mutations that affect DNA repair. These mutations make cancer cells more sensitive to treatments that damage DNA.

• The study involves regular visits every 21 to 28 days for treatment.
• Participants are monitored for cancer progression and side effects.
• Participants can switch treatments if the first one becomes ineffective.

Participants must meet certain health criteria and should not be part of any other drug studies. They will be monitored for health changes throughout the study, which tests if carboplatin or olaparib works better for this cancer type. The study includes 100 men nationwide. Be sure to discuss this study with your doctor to determine if it’s the right fit for you.